Obstetrics and Gynaecology - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/208

Filters

2020 - 2021 2
2
Reset filters

Settings
Statistics
Citations
Start date: 2020 × End date: 2022 × Author: Wark, Suzanne × Author: Mulholland, Edward × Author: Russell, Fiona ×

Search Results

Now showing 1 - 2 of 2
  • Item
    Thumbnail Image
    Human Papillomavirus Vaccination After COVID-19
    Toh, ZQ ; Russell, FM ; Garland, SM ; Mulholland, EK ; Patton, G ; Licciardi, P (OXFORD UNIV PRESS, 2021-04)
    The current global novel coronavirus disease 2019 (COVID-19) pandemic threatens to derail the uptake of human papillomavirus (HPV) vaccination in low- and lower-middle income countries with major disruptions to routine immunization and the introduction of new vaccines delayed. This has a major impact on the World Health Organization cervical cancer elimination strategy, where it is dependent on HPV vaccination as well as cervical cancer screening and treatment. We discuss current opportunities and barriers to achieve high uptake of HPV vaccination in low- and lower-middle income countries as well as the impact of COVID-19. Implementation of 4 key recommendations for HPV vaccination in low- and lower-middle income countries is needed: increased global financial investment; improved vaccine supply and accelerated use of a single-dose schedule; education and social marketing; and adoption of universal school-based delivery. With the commitment of the global health community, the adoption of these strategies would underpin the effective elimination of cervical cancer.
  • Item
    Thumbnail Image
    Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method
    Toh, ZQ ; He, L ; Chen, C ; Huang, A ; Russell, FM ; Garland, SM ; Reyburn, R ; Ratu, T ; Tuivaga, E ; Frazer, IH ; Mulholland, EK ; Licciardi, PV (FRONTIERS MEDIA SA, 2020-10-28)
    Human papillomavirus (HPV) vaccines are safe and effective in preventing HPV infection and cervical precancers. Neutralizing antibodies are thought to be the primary mechanism of protection for HPV vaccines, although the exact level required for protection has not been identified. Three common serological assays used in clinical trials to measure HPV antibodies are HPV pseudovirion-based neutralization assay (PBNA), competitive or total Luminex immunoassays (cLIA or LIA) and VLP-based enzyme linked immunosorbent assays (ELISA). While PBNA is the gold-standard for measuring neutralizing antibodies (NAb), it is labor intensive. Luminex immunoassay and VLP-ELISA are rapid and high throughput, but their reagents and equipment can be difficult to source. Nevertheless, data generated from these assays generally correlate well with PBNA. Here, we described a simplified high-throughput PsV-based ELISA for HPV antibody measurement, to circumvent some of the limitations of existing assays. Using this assay, we were able to differentiate HPV-specific IgG and IgM, and found a strong correlation between HPV-specific IgG and NAb levels, as previously determined by PBNA. This assay platform is simpler and less time-consuming than PBNA. In addition, the materials can be readily produced and obtained commercially. This assay can be used as an alternative method to measure HPV antibodies.